Social Media Ideas for Specialty Drugs

<![CDATA[From Infrastructure to Experience: Why Specialty Therapies Are Reshaping How Organizations Think About Patie...

Why payers should have these 3 pipeline drugs on their radar

Optum Rx's latest look at the drug development pipeline highlights three drugs for rare and chronic conditions that payers and plan sponsors should be watching.

The Private Label Biosimilar Paradox in Medicare Part D

By Tyler Novotny and Bryce Platt PBM-affiliated private label biosimilars would seem to have a built-in formulary advantage. But for ustekinumab, that advantage has not carrie...

How Pharmacy Medical Coding Services Help Specialty Pharmacy Providers Speed Up Insurance Reimbursements

Patients who have cancer, rare diseases, and autoimmune disorders often face high costs of treatment and medication adherence issues. The […] Magellan Solutions - Call Center | BPO...

Medicare Embraces Site-Neutral Payments. Why Haven't Employers?

By Bryce Platt, PharmD Provider-administered drugs are one of the fastest-growing and least-managed cost drivers for commercial plan sponsors. Despite that, recent data from...

Drug Channels News Roundup, August 2026: 340B Rebate Model v2, Patients Feeling Drug Costs, Specialty Drug Spending Driv...

By Bryce Platt, PharmD Kids are heading back to school, but the drug channel never stops handing out homework. Fortunately, we did some of the research prep for you. In this...

A Prescription for Drug Costs: Inject Transparency and Improve Accessibility

Drug spending continues to grow, but that doesn’t mean that everyone is getting the medicines that they need. A panel at MedCity News’ Bullseye event discussed the evolution of the...

The PEPTIDE-L Wave Rolls On! PCAC Adds Two More Bulk Drug Substances for the 503A List

By Charles D. Snow & Karla L. Palmer & Mary Bass —

PEPTIDE-L WAVE! PCAC Approves Four Bulk Drug Substances for the 503A List

By Karla L. Palmer & Charles D. Snow & Mary Bass —

CVS Caremark reaches settlement with FTC over insulin suit

Terms of the deal announced Tuesday are very similar to those the FTC reached with Express Scripts earlier this year, including requiring the PBM to stop preferring higher cost ver...

The billion-dollar problem keeping Ozempic, Wegovy, and Zepbound from patients

Ozempic, Wegovy, and similar drugs may deliver excellent health value, but covering them for millions of eligible patients could overwhelm insurance budgets. Researchers say better...

Supernus, Individor merge to beef up brain drug portfolio

The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster sales for conditions such as opioid use disorder and Pa...

<![CDATA[Your Questions Answered: What This Week's Rare Disease and Specialty Drug News Tells Us About Where the Indu...

Drug Channels News Roundup, Mid-July 2026: Biosimilar Launch Strategy, Part D Spending Trends, Rural 340B Hospitals, Wha...

By Bryce Platt, PharmD Summer's in full swing, but the drug channel didn't take a break. What better way to spend the summer than reading about new pharmacy resources in the...

Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trial

A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a note...

EXCLUSIVE: Drug companies choosing not to sell life-saving and life-extending medicines in Canada

When Ruchi Ambike found out that Novartis got Health Canada approval for Vanrafia she was ecstatic. The drug can possibly slow down the progression of her Immunoglobulin gA nephrop...

Pacira BioSciences: Reimbursement Is Turning An Old Franchise Into A New Growth Platform

An AI drug specialist zeroes in on rare forms of obesity

Superluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but potentially more selectively than — Rhythm Pharmaceuticals...

RC Outsourcing Compounds Medications for Hospitals and Clinics

GLP-1 Compounding Shortage Ends: Report Ranks FormBlends Atop Providers for Supervised Access

The FDA's shortage designations for compounding pharmacies to produce semaglutide and tirzepatide have ended, restricting compounding to cases of documented clinical need. A new re...

<![CDATA[Eli Lilly Surpasses Wall Street Estimates on Injectable GLP-1 Drugs]]>

Affinity AI Launches B2B Marketplace for Compounded Peptides and GLP-1s

A new sourcing portal connects clinics with compounding pharmacies across peptides, GLP-1s, and other compounded therapeutics.

REMS Removed: Why CAR-T’s Expansion into Community Oncology Could Benefit the Big Three Wholesalers

By Greis Kapexhiu and Adam J. Fein, Ph.D. In June 2025, the FDA announced that CAR-T therapies would no longer be subject to a REMS program. The FDA’s removal of CAR-T REMS...

<![CDATA[Why Gross-to-Net Internal Controls Should Be a Launch Priority for Specialty Pharma Companies]]>